Can Periodic Surveillance for Metastases Improve Clinical Outcome in Uveal Melanoma? Moving Towards International Guidelines - European Medical Journal

Can Periodic Surveillance for Metastases Improve Clinical Outcome in Uveal Melanoma? Moving Towards International Guidelines

General Healthcare
Download PDF
Authors:
Joseph J. Sacco,1 Ernie Marshall2
Disclosure:

No potential conflict of interest.

Citation
EMJ Ophth. ;1:8-14.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

Uveal melanoma is a rare disease with a predominant propensity for liver metastasis. Prognosis in the metastatic setting is poor, and no treatments have been proven to extend survival to date. Surveillance for metastases is commonly performed in practice, although there is no unequivocal evidence of its benefit. Surveillance is however intuitively advantageous, allowing locoregional management of liver-only metastases, and facilitating early systemic treatment and particularly trial enrolment, and should, in our view, be considered good clinical practice. Several questions remain, including whom to screen, what modality to use, and for how long. In addition, further investigation is required into the incorporation of novel biomarkers and adjuvant strategies into surveillance.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now